Clinical Trial Update: Neoadjuvant Radiotherapy for Rectal Adenocarcinoma With Capecitabine Versus TAS-102 (Neo-REACT): A Multi-center, Randomized, Phase III Trial [Phase 3]

View source ↗

Summary

A Phase III randomized trial (Neo-REACT) evaluating neoadjuvant radiotherapy with capecitabine versus TAS-102 for rectal adenocarcinoma; the study is currently …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rectal Cancer

Drugs mentioned

• Capecitabine (capecitabine)
• TAS-102 (trifluridine/tipiracil)

Snippet

Sponsor: Shandong Cancer Hospital and Institute | Conditions: Rectal Cancer, Rectal Cancer Patients | Phase 3 | Status: NOT_YET_RECRUITING